# AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis

> **NCT01030328** · PHASE3 · WITHDRAWN · sponsor: **Piedmont Healthcare**

## Conditions studied

- Coronary Atherosclerosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** TriLipix

## Key facts

- **NCT ID:** NCT01030328
- **Lead sponsor:** Piedmont Healthcare
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-11
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of patient population
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01030328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01030328, "AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01030328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*